Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Immunome, Inc. (IMNM : NSDQ)

• Company Description    Immunome, Inc. is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome, Inc. is based in Exton, United States. Number of Employees: 39

• Price / Volume Information    Yesterday's Closing Price: $3.35 Daily Weekly Monthly 20 Day Moving Average: 109,556 shares Shares Outstanding: 12.13 (millions) Market Capitalization: $40.63 (millions) Beta: 0.03 52 Week High: $27.80 52 Week Low: $2.09 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.99% -11.01% 12 Week -52.14% -47.38% Year To Date -74.15% -68.42%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 665 STOCKTON DRIVE SUITE 300 - EXTON,PA 19341 USA ph: 610-321-3700 fax: - investors@immunome.com https://immunome.com

• General Corporate Information    Officers Purnanand D. Sarma - President; Chief Executive Officer and Director Corleen M. Roche - Chief Financial Officer Michael Rapp - Director Richard Baron - Director John LaMattina - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45257U108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/15/22 Share - Related Items Shares Outstanding: 12.13 Most Recent Split Date: (:1) Beta: 0.03 Market Capitalization: $40.63 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.96 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/15/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.07 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -159.46% vs. Previous Quarter: -45.45% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -64.46 12/31/21 - -49.06 09/30/21 - -43.02 ROA 03/31/22 - -55.89 12/31/21 - -43.50 09/30/21 - -39.16 Current Ratio 03/31/22 - 4.77 12/31/21 - 5.82 09/30/21 - 7.88 Quick Ratio 03/31/22 - 4.77 12/31/21 - 5.82 09/30/21 - 7.88 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 3.12 12/31/21 - 3.98 09/30/21 - 4.53 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©